Collaborative Arrangement, Duration Of Agreement

No definition available.

Name:	dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Equity Interest Acquired

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Exclusivity Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Maximum Obligation For Research And Development

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Minimum Obligation For Research And Development

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Option To Extend Exclusivity Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Outstanding Commitment

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Payment for Additional Development and Commercialization

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Payment for Research and Development Agreement

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Revenue Sharing, Percentage

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Prepaid Research and Development

+ References

No definition available.

+ Details

Name:	dyai_PrepaidResearchandDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research and Development Expense, Related Party

+ References

No definition available.

+ Details

Name:	dyai_ResearchandDevelopmentExpenseRelatedParty
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue from Collaborative Arrangement, Recognized

+ References

No definition available.

+ Details

Name:	dyai_RevenueFromCollaborativeArrangementRecognized
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_VLPbioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=dyai_BDIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research Collaboration and Sub-licensing Agreements (Details) € in Thousands					12 Months Ended
	May 07, 2019 antibody_and_vaccine protein	May 05, 2019	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Apr. 26, 2019	Jun. 30, 2017 EUR (€)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Duration of agreement			2 years	2 years
Payment for research and development agreement			$ 1,100,000	€ 1,000
Prepaid Research and Development					$ 0	$ 300,000
Research and development - related party					868,720	$ 1,215,536
Alphazyme [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Equity percentage		7.50%
Ownership interest consideration receivable upon extension of exclusivity period		2.50%
Novovet [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Equity percentage							20.00%
Collaborative Arrangement [Member] \| Alphazyme [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Exclusivity period		18 months
Option to extend exclusivity period		12 months
Collaborative Arrangement [Member] \| Serum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of antibodies and vaccines for development and commercialization \| antibody_and_vaccine	12
Option to obtain exclusive commercial sub-license for number of proteins \| protein	12
Research funding, milestone payments and royalties, period	15 years
Revenue from collaborative arrangement, recognized					$ 118,000
RSA
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment for research and development agreement \| €				€ 1,000
Payment for additional development and commercialization \| €								€ 1,500
RSA \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue sharing, percentage			75.00%	75.00%
RSA \| BDI Holdings
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Equity interest acquired			16.10%	16.10%
RSA \| VLPbio
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Equity interest acquired			3.30%	3.30%
RSA \| BDI
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum \| €								936
Obligation for payment for research and development, maximum \| €								€ 8,000
RSA \| BDI \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA \| BDI \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue sharing, percentage			75.00%	75.00%
SFA
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum			$ 1,000,000
Outstanding commitment			$ 1,000,000